Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Regorafenib Plus Pembrolizumab Misses PFS End Point in Microsatellite Stable CRC

January 22nd 2022

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

Pembrolizumab Triplet Induces Deep, Durable Responses in Some Patients With Treatment-Refractory mCRC

January 22nd 2022

The use of pembrolizumab plus binimetinib and bevacizumab in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer induced a median progression-free survival of 5.8 months, according to preliminary findings from a phase 2 trial.

Onvansertib Plus FOLFIRI/Bevacizumab Generates Meaningful Responses in KRAS-Mutant mCRC

January 22nd 2022

Onvansertib in combination with irinotecan, fluorouracil, and folinic acid, plus bevacizumab, demonstrated encouraging efficacy and was well-tolerated in patients with KRAS-mutated metastatic colorectal cancer.

Frontline Lenvatinib/TACE Improves OS in Advanced HCC

January 22nd 2022

Transarterial chemoembolization plus lenvatinib led to a significant improvement in overall survival vs lenvatinib alone as frontline therapy in patients with advanced hepatocellular carcinoma, according to findings from the phase 3 LAUNCH trial.

Dr. Oh on the Results of the TOPAZ-1 Trial in Advanced Biliary Tract Cancer

January 22nd 2022

Do-Youn Oh, MD, PhD, discusses the results of the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

Dr. Bekaii-Saab on the Updated Results of the KRYSTAL-1 Trial in KRAS G12C+ GI Cancers

January 22nd 2022

Tanios S. Bekaii-Saab, MD, FACP, discusses the updated results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C-mutated gastrointestinal cancers, including pancreatic ductal adenocarcinoma.

Olaparib Plus Pembrolizumab Demonstrates Manageable AEs in Advanced Cholangiocarcinoma

January 22nd 2022

The combination of olaparib and pembrolizumab demonstrated acceptable safety and an manageable adverse effect profile in patients with advanced cholangiocarcinoma who had received prior gemcitabine-based therapy, according to findings from a phase 2 trial.

Pembrolizumab/Chemo Combo Emerges as Standard of Care in Esophageal Cancer/GEJ Adenocarcinoma

January 21st 2022

Updated findings from the KEYNOTE-590 study confirmed the clinical benefit of the combination of pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer.

TACE Combined With Lenvatinib and Sunitinib May Be a Safe, Tolerable Treatment Option for Unresectable HCC

January 21st 2022

Transarterial chemoembolization combined with lenvatinib plus sintilimab was safe and effective for patients with unresectable hepatocellular carcinoma.

Lenvatinib May Provide Survival Benefit With Manageable Toxicities in Recurrent HCC After Liver Transplantation

January 21st 2022

Lenvatinib was effective in treating patients with recurrent hepatocellular carcinoma after liver transplantation and demonstrated manageable toxicities.

Nivolumab/Chemo Combo Maintains Clinical Efficacy at 2 Years in Gastric/GEJ Cancer

January 21st 2022

Nivolumab plus chemotherapy demonstrated a durable survival benefit for patients with gastric or gastroesophageal junction cancer, according to updated findings from the CheckMate 649 trial.

Sintilimab Plus Standard Chemotherapy Misses OS End Point in Metastatic Pancreatic Cancer

January 21st 2022

Sintilimab plus standard-of-care chemotherapy failed to demonstrate a significant improvement in overall survival and progression-free survival vs standard-of-care chemotherapy alone but did result in an improved objective response rate in patients with metastatic or recurrent pancreatic adenocarcinoma, according to findings from the phase 3 CISPD3 trial.

Oral Fluoropyrimidine Improves Survival as Adjuvant Therapy in Biliary Tract Cancer

January 21st 2022

The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers.

Adagrasib Monotherapy Elicits High Rates of Disease Control in KRAS-Mutated PDAC and Other GI Malignancies

January 21st 2022

Adagrasib monotherapy demonstrated encouraging clinical activity in patients with previously treated pancreatic ductal adenocarcinoma and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations.

FDA Grants Orphan Drug Designation to Silmitasertib for Biliary Tract Cancer

January 21st 2022

The FDA has granted an orphan drug designation to silmitasertib for use as a potential therapeutic option in patients with biliary tract cancer.

Frontline Pembrolizumab Monotherapy, Plus Chemo Shows Mixed OS Findings in PD-L1+ Gastric/GEJ Adenocarcinoma

January 20th 2022

Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.

Key Markers in Gut Microbiome May Predict Skin-Related AEs With Nivolumab in Advanced Gastric Cancer

January 20th 2022

The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events in patients with advanced gastric cancer who are receiving single-agent nivolumab.

Neoadjuvant Nivolumab/Ipilimumab Produces High pCR Rate in MSI/dMMR Oeso-Gastric Adenocarcinoma

January 20th 2022

Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab elicited a pathologic complete response rate of 59% in patients with resectable microsatellite instable or mismatch repair deficient oeso-gastric junction adenocarcinoma.

FDA Grants Orphan Drug Designation to MT-601 for Pancreatic Cancer

January 20th 2022

The FDA’s Office of Orphan Products Development has granted an orphan drug designation to the multitumor-associated antigen-specific T-cell therapy, MT-601, for the treatment of patients with pancreatic cancer.

Durvalumab Plus Tremelimumab Improves OS in Unresectable HCC

January 18th 2022

The combination of durvalumab and tremelimumab demonstrated a significant improvement in overall survival vs sorafenib as frontline therapy in patients with unresectable hepatocellular carcinoma, according to findings from the phase 3 HIMALAYA trial.